We are live on ! Find out more
ZBIO

Zenas BioPharma
ZBIO

65 hedge funds and large institutions have $260M invested in Zenas BioPharma in 2024 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 13 increasing their positions, 7 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 14

86% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 7

48% more funds holding

Funds holding: 44 → 65 (+21)

13.6% more ownership

Funds ownership: 62.25% → 75.85% (+14%)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

38% less capital invested

Capital invested by funds: $419M → $260M (-$159M)

Holders
65
Holders Change
+21
Holders Change %
+47.73%
% of All Funds
0.86%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
35
Increased
13
Reduced
7
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$15.7M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$12.9M
3
NHAS
Novo Holdings A/S
Denmark
+$7.02M
4
ACH
ArrowMark Colorado Holdings
Colorado
+$5.11M
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$5.05M

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$6.24M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$5.71M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$3.4M
4
MIM
Monashee Investment Management
Massachusetts
-$2.54M
5
Goldman Sachs
Goldman Sachs
New York
-$1.41M
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
26
UBS Group
Switzerland
$1.08M +$2.05M +131,606 +223,061%
Northern Trust
27
Northern Trust
Illinois
$1.02M +$1.94M +124,246 New
Charles Schwab
28
Charles Schwab
California
$972K +$1.85M +118,660 New
SCM
29
Superstring Capital Management
New York
$914K – – –
Citadel Advisors
30
Citadel Advisors
Florida
$677K -$182K -11,698 -12%
Norges Bank
31
Norges Bank
Norway
$542K -$137K -8,798 -12%
M&T Bank
32
M&T Bank
New York
$512K +$589K +37,738 +152%
GCP
33
GSA Capital Partners
United Kingdom
$459K +$874K +56,039 New
Goldman Sachs
34
Goldman Sachs
New York
$345K -$1.41M -90,226 -68%
RhumbLine Advisers
35
RhumbLine Advisers
Massachusetts
$319K +$607K +38,942 New
Renaissance Technologies
36
Renaissance Technologies
New York
$314K +$599K +38,400 New
Bank of New York Mellon
37
Bank of New York Mellon
New York
$294K +$561K +35,944 New
AA
38
ALPS Advisors
Colorado
$277K +$527K +33,790 New
JP Morgan Chase
39
JP Morgan Chase
New York
$244K +$465K +29,839 New
Barclays
40
Barclays
United Kingdom
$196K +$132K +8,439 +54%
Deutsche Bank
41
Deutsche Bank
Germany
$188K +$359K +22,990 New
Bank of America
42
Bank of America
North Carolina
$177K +$337K +21,575 New
N
43
Nuveen
North Carolina
$163K +$311K +19,909 New
BNP Paribas Financial Markets
44
BNP Paribas Financial Markets
France
$149K +$285K +18,245 New
Two Sigma Investments
45
Two Sigma Investments
New York
$140K +$63.1K +4,045 +31%
BC
46
Birchview Capital
Vermont
$135K +$257K +16,500 New
Citigroup
47
Citigroup
New York
$99.1K +$189K +12,104 New
SIP
48
Stoneridge Investment Partners
Pennsylvania
$90K +$171K +10,955 New
MIM
49
MetLife Investment Management
New Jersey
$83.7K +$159K +10,225 New
Mirae Asset Global ETFs Holdings
50
Mirae Asset Global ETFs Holdings
Hong Kong
$70.4K +$134K +8,596 New
1
2
3 4

ZBIO Hedge Fund Activity: Q4 2024 in Review

65 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Zenas BioPharma (ZBIO) for Q4 2024, worth a combined $260M — down 38% from $419M a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new ZBIO positions and 14 closed out — a net gain of 21 holders — while 13 added to existing stakes and 7 trimmed.

The largest buyer was BlackRock, opening a new position worth an estimated $15.7M. The largest seller was Perceptive Advisors, cutting an estimated $6.24M.

  • 65 institutional investors held Zenas BioPharma (ZBIO) as of Q4 2024, up from 44 in Q3 2024.
  • Funds reported $260M of Zenas BioPharma stock for Q4 2024, down 38% quarter-over-quarter.
  • 35 funds opened new Zenas BioPharma positions in Q4 2024 and 14 closed out, a net change of +21 holders.
  • The largest Zenas BioPharma buyer in Q4 2024 was BlackRock, an estimated $15.7M added.
  • The largest Zenas BioPharma seller in Q4 2024 was Perceptive Advisors, an estimated $6.24M sold.

Based on aggregated 13F filings for Q4 2024.